Related Experiment Video
Updated: Mar 12, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
New Biomarkers for Selecting the Best Therapy Regimens in Metastatic Castration-Resistant Prostate Cancer
Isabel Heidegger1, Axel Heidenreich2, David Pfister2
1Department of Urology, University Hospital Cologne, Kerpener Strasse 62, 50937, Cologne, Germany. Isabel.heidegger@uk-koeln.de.
Abstract:
Prostate cancer is the most common cancer in men. In recent years, several new targeted therapeutic agents for the treatment of metastatic castration resistant prostate cancer (mCRPC) have been developed. These include androgen receptor targeting agents, new taxanes, radium-223, and immunotherapies. In this short review, we provide a summary of clinical and preclinical biomarkers for each of these new treatment strategies, also including new markers currently presented in conference papers only. Moreover, we address the role of these biomarkers in clinical routine with the aim to select best-personalized treatment strategies for patients. Finally, we provide a decision tree for selecting the proper therapy for patients with mCRPC according to the discussed biomarkers.
Insights
New biomarkers are emerging for advanced prostate cancer treatments. This review summarizes these markers to guide personalized therapy selection for metastatic castration-resistant prostate cancer (mCRPC).
Area of Science:
- Oncology
- Medical Biomarkers
- Prostate Cancer Research
Background:
- Prostate cancer is a leading cancer in men.
- Metastatic castration-resistant prostate cancer (mCRPC) has seen advancements in targeted therapies.
- New treatment classes include androgen receptor agents, taxanes, radium-223, and immunotherapies.
Purpose of the Study:
- To review clinical and preclinical biomarkers for novel mCRPC therapies.
- To discuss the role of biomarkers in routine clinical practice for personalized treatment.
- To present emerging biomarkers from recent conference proceedings.
Main Methods:
- Literature review of clinical and preclinical studies.
- Analysis of biomarker data for targeted agents.
- Synthesis of information on novel therapeutic strategies.
Main Results:
- Identification of key biomarkers for androgen receptor agents, taxanes, radium-223, and immunotherapies.
- Evaluation of biomarker utility in patient selection for mCRPC.
- Inclusion of recently presented, pre-publication biomarker data.
Conclusions:
- Biomarkers are crucial for personalizing mCRPC treatment.
- A decision tree is proposed to guide therapy selection based on biomarkers.
- Ongoing research continues to identify new predictive and prognostic markers.
More Related Videos
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019